Merck bags imperfect immunotherapy first with Keytruda cervical cancer approval aliu Thu, 10/14/2021 – 10:27 More: Merck bags imperfect immunotherapy first with Keytruda cervical cancer approval Source: fierce
read moreBristol Myers Squibb is nixing BeiGene’s Abraxane deal in China amid manufacturing woes. Is their cancer rivalry really to blame? aliu Thu, 10/14/2021 – 09:34 More: Bristol Myers Squibb is nixing BeiGene's Abraxane deal in China amid manufacturing woes. Is
read moreThe ATTC is coordinated as part of the Cell and Gene Therapy Catapult, and operates within the NHS framework More: Innovate UK funded NA-ATTC adds three new industry partners Source: News
read moreKeytruda plus chemotherapy demonstrated superior overall survival rate in this patient population in the KEYNOTE-826 trial More: FDA clears Keytruda for first-line cervical cancer Source: News
read moreThe measures include a £250m ‘winter access fund’ from NHS England More: NHS publishes new plans to improve patient access to GP appointments Source: News
read more26 experts have been appointed to join the Scientific Advisory Group on the Origins of Novel Pathogens (Sago) More: New WHO group could be ‘the last to find virus origins’ Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals